Invega Sustenna 75 mg

Invega Sustenna 75 mg is an extended-release suspension of paliperidone palmitate, used for managing certain mental health conditions. This intramuscular injection is designed for long-term administration.

Invega Sustenna 75 mg is primarily used for the treatment of schizophrenia in adults. This medication is part of a long-acting injectable therapy, which may help maintain stable levels of the active ingredient over time. Paliperidone palmitate, the active compound, is designed to provide continuous symptom management, reducing the need for frequent dosing.

Common effects of Invega Sustenna 75 mg may include injection site reactions, weight gain, and drowsiness. Some individuals might experience changes in appetite or mild gastrointestinal discomfort. These effects can vary widely among users, and it's important to monitor any unusual symptoms.

Invega Sustenna 75 mg should be administered by a healthcare professional. It is crucial to inform your healthcare provider about any allergies or medical conditions before starting this medication. Regular monitoring may be necessary to ensure the safe and effective use of this extended-release suspension.

Invega Sustenna 75 mg may interact with other medications, including those that affect the central nervous system. Alcohol and certain CYP inhibitors might also influence the effectiveness or safety of this medication. Always consult a healthcare provider before combining Invega Sustenna with other treatments.